Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny
The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.
Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
Generic companies using skinny labeling should not receive preferential treatment for inducement purposes, as consistent inducement laws should be applied uniformly.
Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny
The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.
Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
Generic companies using skinny labeling should not receive preferential treatment for inducement purposes, as consistent inducement laws should be applied uniformly.
Can EU wean itself off essential drugs from China, India? DW 05/07/2024
Europe is vulnerable to China's influence by cutting off antibiotic supplies, and establishing a pharmaceutical database is crucial for securing medicinal products.